China investment... cancer and autoimmune

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Stock2740

Rank: Treasurer [?]

Points: 330 [?]

Votes: 10 Score: 2.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

China investment... cancer and autoimmune

posted on Dec 30, 2015 09:58AM

I wouldn't be surprized to see hepalink take out an equal placement in sister company , heck its only another 35 million !

I believe the merets to invest in Resverlogix have peaked there desire to remain fluid within both cutting edge epigenetic platforms of selective BET inhibitors. Mini Pharma becomes Big Pharma

just my two pennies , Stock

Anyhow, we will all find out the Real goods January 7, 2016 (happy new year all !)

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply